Based in the United States, Geneos Therapeutics is a startup.
Geneos Therapeutics has developed GT-EPIC™, a platform to generate personalized cancer immunotherapies that target tumour-specific neoantigens. The company is developing treatments for solid tumours starting with hepatocellular carcinoma and reported several complete responses in a phase Ib/IIa trial published in Nature Medicine.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.